Skip to Content

Join the 'Hepatitis C' group to help and get support from people like you.

Hepatitis C News

Related terms: Hepatitis C, Chronic, Chronic Hepatitis C, Hep C

Patent Monopolies Driving High U.S. Drug Prices: Study

Posted 3 days ago by Drugs.com

TUESDAY, Aug. 23, 2016 – Prescription drug prices are skyrocketing in the United States due in large part to government regulations, a new analysis finds. These regulations allow drug manufacturers to charge monopolistic prices that aren't opposed by competing market forces, the researchers believe. The result? For each person in the United States, $858 was spent on prescription drugs, compared with an average of $400 per person across 19 other industrialized nations. Prescription medications now comprise an estimated 17 percent of overall health care expenses, the authors of the new report said. Drug makers charge high prices for drugs thanks largely to "market exclusivity" regulations intended to allow them to recoup the research and development costs for new breakthrough medications, said senior author Ameet Sarpatwari. He's an instructor at Harvard Medical School and the Harvard ... Read more

Related support groups: Allergic Reactions, Hepatitis C, Anaphylaxis, EpiPen, Daraprim

Serious Infections Tied to Suicide Risk

Posted 16 days ago by Drugs.com

WEDNESDAY, Aug. 10, 2016 – People hospitalized for serious infections may face an increased risk of dying by suicide, and researchers suspect there's a biological reason for it. In a study of over 7 million people, Danish researchers found that those who'd been hospitalized for infections were 42 percent more likely to die of suicide compared to people with no history of serious infection. People hospitalized for HIV/AIDS or the liver infection hepatitis showed the highest risk – more than twice that of people without those diseases, the study found. Although the study couldn't prove a cause-and-effect link, the study authors and at least one other brain health expert think the increased risk of suicide after infection might not simply reflect the psychological impact of serious illness. Instead, infections might directly contribute to suicide risk by causing inflammation in the ... Read more

Related support groups: Depression, Major Depressive Disorder, Hepatitis C, HIV Infection, Postpartum Depression, Hepatitis B, Dysthymia, Seasonal Affective Disorder, Hepatitis A, Neurotic Depression, Depressive Psychosis, Chronic Active Hepatitis, Infectious Hepatitis

AbbVie Receives U.S. FDA Approval of Once-Daily Viekira XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C

Posted 28 Jul 2016 by Drugs.com

NORTH CHICAGO, Ill., July 25, 2016 /PRNewswire/ – AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for Viekira XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) extended-release tablets. Viekira XR is a once-daily, extended-release co-formulation of the active ingredients in Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) and is for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis (Child-Pugh A). Viekira XR is not for people with decompensated cirrhosis. Viekira XR is the first co-formulated three direct-acting antiviral (DAA) treatment for adult patients with GT1 HCV. Viekira XR is given once-daily as three oral tablets and must be taken with a meal. ... Read more

Related support groups: Hepatitis C, Hepatitis, Viekira Pak, Viekira XR, Dasabuvir/ombitasvir/paritaprevir/ritonavir

Epclusa Approved for Chronic Hepatitis C

Posted 29 Jun 2016 by Drugs.com

TUESDAY, June 28, 2016 – The combination drug Epclusa has been approved by the U.S. Food and Drug Administration to treat the six major strains of chronic hepatitis C virus (HCV). Epclusa combines sofosbuvir, FDA-approved in 2013, and the new drug velpatasvir. For people with moderate-to-severe cirrhosis (chronic liver disease), Epclusa is approved to be used in combination with the drug ribavirin. Epclusa also is approved for use in people who haven't developed cirrhosis, the agency said Tuesday in a news release. HCV causes liver inflammation and diminished liver function. Some 75 percent of Americans with the disease have genotype 1, although there are five other strains. The disease typically becomes chronic, leading to possible complications including bleeding, yellowing of the skin and eyes (jaundice), abdominal fluid accumulation and liver cancer. It could lead to death. Epclusa ... Read more

Related support groups: Hepatitis C, Sofosbuvir, Epclusa, Sofosbuvir/velpatasvir

FDA Approves Epclusa (sofosbuvir and velpatasvir) for Treatment of all Major Forms of Chronic Hepatitis C Virus Infection

Posted 28 Jun 2016 by Drugs.com

June 28, 2016 – The U.S. Food and Drug Administration approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease). For patients with moderate to severe cirrhosis (decompensated cirrhosis), Epclusa is approved for use in combination with the drug ribavirin. Epclusa is a fixed-dose combination tablet containing sofosbuvir, a drug approved in 2013, and velpatasvir, a new drug, and is the first to treat all six major forms of HCV. “This approval offers a management and treatment option for a wider scope of patients with chronic hepatitis C,” said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research. Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. There are at least six ... Read more

Related support groups: Hepatitis C, Sovaldi, Sofosbuvir, Epclusa, Sofosbuvir/velpatasvir

Hepatitis C Patients More Likely to Drink, Study Finds

Posted 25 May 2016 by Drugs.com

WEDNESDAY, May 25, 2016 – People infected with hepatitis C are more likely to be current or former heavy drinkers, a new study suggests. Unfortunately, alcohol may accelerate the liver damage associated with the virus, the researchers added. Adults with hepatitis C were three times more likely to have five or more drinks daily – currently or in the past – than people who didn't have the virus, according to the study published recently in the American Journal of Preventive Medicine. "Alcohol promotes faster development of fibrosis and progression to cirrhosis [scarring of the liver] in people living with hepatitis C, making drinking a dangerous and often deadly activity," said lead investigator Amber Taylor, from the U.S. Centers for Disease Control and Prevention's Division of Viral Hepatitis. "In 2010, alcohol-related liver disease ranked third as a cause of death among people with ... Read more

Related support groups: Hepatitis C, Alcohol Dependence, Alcoholism, Hangover, Alcoholic Liver Damage, Acute Alcohol Intoxication, Alcohol Hepatitis

Hepatitis C Now Leading Infectious Disease Killer in U.S.

Posted 4 May 2016 by Drugs.com

WEDNESDAY, May 4, 2016 – The number of hepatitis C-linked deaths in the United States reached a record high in 2014, and the virus now kills more Americans than any other infectious disease, health officials report. There were 19,659 hepatitis C-related deaths in 2014, according to preliminary data from U.S. Centers for Disease Control and Prevention. Those tragically high numbers aren't necessary, one CDC expert said. "Why are so many Americans dying of this preventable, curable disease? Once hepatitis C testing and treatment are as routine as they are for high cholesterol and colon cancer, we will see people living the long, healthy lives they deserve," said Dr. Jonathan Mermin said in an agency news release. He directs the CDC's National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. If not diagnosed and treated, people with hepatitis C are at increased risk for liver ... Read more

Related support groups: Infections, Hepatitis C, Infectious Hepatitis

Generic Hepatitis C Drugs as Effective as Pricey Brand Names: Study

Posted 18 Apr 2016 by Drugs.com

SATURDAY, April 16, 2016 – Low-cost generic antiviral drugs are as effective and safe as more expensive brand-name drugs in treating people with hepatitis C, researchers report. In many countries, people don't have access to a course of brand-name direct-acting antiviral drugs due to the high cost – as much as $94,000 a patient, the researchers explained. However, mass-produced generic versions are available for less than 1 percent of the retail price of the brand-name drugs, they added. "Our interim data suggests a potential solution for hepatitis C patients in areas where treatment access has been restricted as a result of the high prices demanded for branded treatment," said study author Dr. James Freeman, of GP2U Telehealth in Hobart, Australia. The study of patients in the United States, Canada, Africa, Australia, Europe and Southeast Asia found that generic direct-acting ... Read more

Related support groups: Hepatitis C, Harvoni, Ribavirin, Sovaldi, Sofosbuvir, Liver and Pancreatic Disease, Copegus, Ribasphere, Daklinza, Rebetol, Ledipasvir/sofosbuvir, Interferon Alfa-2B/Ribavirin, RibaPak, Rebetron, Virazole, Hepatic Tumor, Daclatasvir, Moderiba, RibaTab

Hepatitis C Therapy May Reduce Need for Liver Transplants

Posted 15 Apr 2016 by Drugs.com

THURSDAY, April 14, 2016 – Treatment with antiviral drugs may reduce the need for a liver transplant for people with severe liver damage and hepatitis C, a new study suggests. This study included 103 liver transplant candidates in Europe with severe liver damage and hepatitis C. They were treated with direct-acting antiviral drug combinations used to treat and cure people with hepatitis C. Thirty-five percent of the patients improved to the point where they were no longer in urgent need of a liver transplant. And 20 percent got so much better that they no longer needed a transplant, researchers found. Currently, more than 15,000 people in the United States are on the liver transplant waiting list. About 16 percent will die before receiving a new liver. And roughly 30 percent of adults on the liver transplant waiting list have severe liver damage and hepatitis C, the researchers said. ... Read more

Related support groups: Hepatitis C

Hepatitis C-Infected Liver Transplants May Work Well for Those With the Virus

Posted 15 Apr 2016 by Drugs.com

THURSDAY, April 14, 2016 – Here's some potentially good news for people with hepatitis C who are waiting for liver transplants: Hepatitis C-infected livers seem to do as well as healthy livers in these patients, a new study indicates. The findings suggest that using hepatitis C-infected (HCV-positive) livers could help reduce wait times for people with hepatitis C who need a transplant, the researchers said. Hepatitis C is a virus that can infect the liver, leading to inflammation, scarring and liver cancer. More than 15,000 people in the United States are on the liver transplant waiting list, and about 16 percent will die before they receive a new liver, according to background notes with the study. In the United States, use of HCV-positive livers for liver transplants in people with hepatitis C has tripled, from less than 3 percent in 1995 to more than 9 percent in 2013. Researchers ... Read more

Related support groups: Hepatitis C, Liver and Pancreatic Disease, Organ Transplant - Rejection Reversal, Rejection Reversal

Head and Neck Cancers May Be Linked to Hepatitis C

Posted 13 Apr 2016 by Drugs.com

WEDNESDAY, April 13, 2016 – Hepatitis C may increase the risk for certain types of head and neck cancers, researchers say. Hepatitis C is a serious liver infection caused by a virus. It's the most common bloodborne infection in the United States, affecting as many as 3.5 million people, according to the U.S. Centers for Disease Control and Prevention. Many are unaware they have the infection. "What we are trying to make all understand is that this is an infection that has consequences – and it's an infection we can cure," said study leader Dr. Harrys Torres, an associate professor of infectious diseases at the University of Texas MD Anderson Cancer Center. It's already known that people with hepatitis C have a significantly higher risk of liver cancers and non-Hodgkin's lymphoma, according to the researchers. Antiviral drugs cure more than 90 percent of hepatitis C cases, and ... Read more

Related support groups: Cancer, Hepatitis C, Head and Neck Cancer, Salivary Gland Cancer

Ridding U.S. of Hepatitis B, C as 'Public Health Problem' Possible: Experts

Posted 11 Apr 2016 by Drugs.com

MONDAY, April 11, 2016 – Experts say there's real hope in someday ridding the United States of the "public health problem" of hepatitis B and C infection. The two viral strains cause serious, often fatal, liver disease for tens of thousands of Americans each year. The comprehensive new report is from a panel of experts at the U.S. National Academies of Sciences, Engineering, and Medicine. They believe that the advent of a powerful new vaccine and medicines could help drastically lower hepatitis B and C rates across the country. Still, to reach that goal will take time and considerable resources, the report said. "Ending illness and deaths from hepatitis C depends on both stopping the disease's progression in its early stages and reversing the course of advanced disease," the committee said in a news release. According to the report, between 700,000 and 1.4 million Americans have ... Read more

Related support groups: Hepatitis C, Cirrhosis, Hepatitis B, Liver Cirrhosis, Exposure to Hepatitis B Virus, Hepatic Tumor

U.S. Cancer Death Rate Continues to Fall

Posted 9 Mar 2016 by Drugs.com

WEDNESDAY, March 9, 2016 – Overall rates of cancer and deaths from cancer in the United States continue to decline, a newly released report says. However, an increase in liver cancer deaths is cause for concern, the report authors noted. An increase in hepatitis C infections is likely a major reason for the increase, they said. "The latest data show many cancer prevention programs are working and saving lives," Dr. Tom Frieden, director of the U.S. Centers for Disease Control and Prevention, said in a news release from the organizations that issued the report. "But the growing burden of liver cancer is troublesome. We need to do more work promoting hepatitis testing, treatment, and vaccination," Frieden added. The Report to the Nation on the Status of Cancer is released each year by the American Cancer Society, the U.S. Centers for Disease Control and Prevention, the National Cancer ... Read more

Related support groups: Cancer, Smoking, Hepatitis C, Breast Cancer, Prostate Cancer, Smoking Cessation, Cirrhosis, Lung Cancer, Colorectal Cancer, Hepatitis B, Basal Cell Carcinoma, Brain Tumor, Liver Cirrhosis, Melanoma, Skin Cancer, Ovarian Cancer, Bladder Cancer, Melanoma - Metastatic, Cervical Cancer, Stomach Cancer

FDA Approves Expanded Use of Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C

Posted 24 Feb 2016 by Drugs.com

PRINCETON, N.J., February 5, 2016 --(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that Daklinza (daclatasvir, 60 mg), an NS5A replication complex inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) in combination with sofosbuvir (with or without ribavirin) in genotypes 1 and 3. The expanded label includes data in three additional challenging-to-treat patient populations: chronic hepatitis C virus (HCV) patients with HIV-1 coinfection, advanced cirrhosis, or post-liver transplant recurrence of HCV. The Daklinza plus sofosbuvir regimen is already available for the treatment of chronic HCV genotype 3, and is currently the only 12-week, once-daily all-oral treatment option for these patients. Sustained virologic response (SVR) rates are reduced in genotype 3 patients with cirrhosis receiving Daklinza and sofosbuvir for 12 weeks without ... Read more

Related support groups: Hepatitis C, Daklinza, Daclatasvir

FDA Approves Two Supplemental Indications for Harvoni in Chronic Hepatitis C Patients With Advanced Liver Disease

Posted 18 Feb 2016 by Drugs.com

FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 16, 2016-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved additional indications for Harvoni (ledipasvir/sofosbuvir) for use in chronic hepatitis C patients with advanced liver disease. Harvoni in combination with ribavirin (RBV) for 12 weeks was approved for use in chronic hepatitis C virus (HCV) genotype 1- or 4-infected liver transplant recipients without cirrhosis or with compensated cirrhosis (Child-Pugh A), and for HCV genotype 1-infected patients with decompensated cirrhosis (Child-Pugh B or C), including those who have undergone liver transplantation. Harvoni is now approved for use in a broader range of patient populations, including HCV genotypes 1, 4, 5 and 6, HCV/HIV-1 coinfection, HCV genotype 1 and 4 liver transplant recipients, and genotype 1-infected patients ... Read more

Related support groups: Hepatitis C, Harvoni, Ledipasvir/sofosbuvir

Page 1 2 3 4 5 6 7 8 9 Next

Ask a Question

Further Information

Related Condition Support Groups

Infectious Hepatitis

Related Drug Support Groups

Harvoni, ribavirin, Sovaldi, Incivek, Pegasys, Victrelis, PegIntron, sofosbuvir, interferon alfa-2b, view more... Viekira Pak, Ribasphere, Copegus, telaprevir, Daklinza, Zepatier, boceprevir, Rebetol, ledipasvir / sofosbuvir, interferon alfa-2a, interferon alfa-2b / ribavirin, Epclusa, Intron A, Olysio, Rebetron, peginterferon alfa-2b, RibaPak, peginterferon alfa-2a, Technivie, daclatasvir, Viekira XR, ombitasvir / paritaprevir / ritonavir, Roferon-A, simeprevir, RibaTab, dasabuvir / ombitasvir / paritaprevir / ritonavir, Moderiba, elbasvir / grazoprevir, Infergen, interferon alfacon-1, sofosbuvir / velpatasvir